Literature DB >> 19066331

Treatment of light chain deposition disease with bortezomib and dexamethasone.

Efstathios Kastritis, Magdalini Migkou, Maria Gavriatopoulou, Panos Zirogiannis, Valsamakis Hadjikonstantinou, Meletios A Dimopoulos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19066331      PMCID： PMC2635400          DOI： 10.3324/haematol.13548

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

Review 1.  Light chain deposition disease: a model of glomerulosclerosis defined at the molecular level.

Authors:  Pierre M Ronco; Marie-Alexandra Alyanakian; Beatrice Mougenot; Pierre Aucouturier
Journal:  J Am Soc Nephrol       Date:  2001-07       Impact factor: 10.121

Review 2.  Nonamyloidotic monoclonal immunoglobulin deposition disease. Light-chain, heavy-chain, and light- and heavy-chain deposition diseases.

Authors:  J Buxbaum; G Gallo
Journal:  Hematol Oncol Clin North Am       Date:  1999-12       Impact factor: 3.722

3.  Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice.

Authors:  Orianne Wagner-Ballon; Didier F Pisani; Thomas Gastinne; Micheline Tulliez; Ronan Chaligné; Catherine Lacout; Frédéric Auradé; Jean-Luc Villeval; Patrick Gonin; William Vainchenker; Stéphane Giraudier
Journal:  Blood       Date:  2007-03-20       Impact factor: 22.113

4.  Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

Authors:  Asher A Chanan-Khan; Jonathan L Kaufman; Jayesh Mehta; Paul G Richardson; Kena C Miller; Sagar Lonial; Nikhil C Munshi; Robert Schlossman; Joseph Tariman; Seema Singhal
Journal:  Blood       Date:  2006-11-30       Impact factor: 22.113

5.  Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease.

Authors:  R L Heilman; J A Velosa; K E Holley; K P Offord; R A Kyle
Journal:  Am J Kidney Dis       Date:  1992-07       Impact factor: 8.860

6.  NF-kappa B as a therapeutic target in multiple myeloma.

Authors:  Teru Hideshima; Dharminder Chauhan; Paul Richardson; Constantine Mitsiades; Nicholas Mitsiades; Toshiaki Hayashi; Nikhil Munshi; Lenny Dang; Alfredo Castro; Vito Palombella; Julian Adams; Kenneth C Anderson
Journal:  J Biol Chem       Date:  2002-02-28       Impact factor: 5.157

Review 7.  The mesangium as a target for glomerulopathic light and heavy chains: pathogenic considerations in light and heavy chain-mediated glomerular damage.

Authors:  John Keeling; Guillermo A Herrera
Journal:  Contrib Nephrol       Date:  2007       Impact factor: 1.580

Review 8.  Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors.

Authors:  Claudio Pozzi; Marco D'Amico; Giovanni B Fogazzi; Simona Curioni; Franco Ferrario; Sonia Pasquali; Giacomo Quattrocchio; Cristiana Rollino; Siro Segagni; Francesco Locatelli
Journal:  Am J Kidney Dis       Date:  2003-12       Impact factor: 8.860

9.  Long-term outcome of autologous stem cell transplantation in light chain deposition disease.

Authors:  Elizabeth C Lorenz; Morie A Gertz; Fernando C Fervenza; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Dennis A Gastineau; Nelson Leung
Journal:  Nephrol Dial Transplant       Date:  2008-01-04       Impact factor: 5.992

10.  High dose chemotherapy in light chain or light and heavy chain deposition disease.

Authors:  Bruno Royer; Bertrand Arnulf; Frank Martinez; Lydia Roy; Béatrice Flageul; Isabelle Etienne; Pierre Ronco; Jean-Claude Brouet; Jean-Paul Fermand
Journal:  Kidney Int       Date:  2004-02       Impact factor: 10.612
View more
  18 in total

1.  Portal hypertension related to light chain deposition disease of liver: an enlightening experience.

Authors:  Arunansu Talukdar; Kabita Mukherjee; Dibbendhu Khanra; Manjari Saha
Journal:  BMJ Case Rep       Date:  2013-05-29

2.  Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease.

Authors:  Camille Cohen; Bruno Royer; Vincent Javaugue; Raphael Szalat; Khalil El Karoui; Alexis Caulier; Bertrand Knebelmann; Arnaud Jaccard; Sylvie Chevret; Guy Touchard; Jean-Paul Fermand; Bertrand Arnulf; Frank Bridoux
Journal:  Kidney Int       Date:  2015-07-15       Impact factor: 10.612

3.  Gamma 1-heavy chain deposition disease accompanied by IgG kappa in serum, urine, and bone marrow.

Authors:  Keiichi Kaneko; Koichi Seta; Jun Soma; Takashi Kuwahara; Mitsuteru Koizumi; Yuko Kikuchi; Akira Sugawara; Kensei Yahata
Journal:  CEN Case Rep       Date:  2013-07-10

4.  Rheumatoid arthritis and renal light-chain deposition disease: long-term effectiveness of TNF-α blockade with etanercept.

Authors:  Lorenzo Cavagna; Vincenzo Sepe; Francesca Bobbio-Pallavicini; Filippo Mangione; Roberto Caporali; Carlomaurizio Montecucco
Journal:  Int Urol Nephrol       Date:  2010-06-18       Impact factor: 2.370

5.  Durable hematological response and improvement of nephrotic syndrome on thalidomide therapy in a patient with refractory light chain deposition disease.

Authors:  Haruyuki Fujita; Masakatsu Hishizawa; Soichiro Sakamoto; Tadakazu Kondo; Norimistu Kadowaki; Takayuki Ishikawa; Junji Itoh; Atsushi Fukatsu; Takashi Uchiyama; Akifumi Takaori-Kondo
Journal:  Int J Hematol       Date:  2011-04-09       Impact factor: 2.490

6.  Hypertension, renal failure, and edema in a 38-year-old man: light chain deposition disease; a case report and review of the literature.

Authors:  Sarmad Said; Chad J Cooper; Azikiwe C Nwosu; Jorge E Bilbao; German T Hernandez
Journal:  J Nephropathol       Date:  2014-04-01

Review 7.  Paraprotein-Related Kidney Disease: Glomerular Diseases Associated with Paraproteinemias.

Authors:  Shveta S Motwani; Leal Herlitz; Divya Monga; Kenar D Jhaveri; Albert Q Lam
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

Review 8.  Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.

Authors:  Jacob P Laubach; Constantine S Mitsiades; Aldo M Roccaro; Irene M Ghobrial; Kenneth C Anderson; Paul G Richardson
Journal:  Leuk Lymphoma       Date:  2009-05

9.  Late recurrence of light chain deposition disease after kidney transplantation treated with bortezomib: a case report.

Authors:  Abdul Moiz; Tariq Javed; Jorge Garces; Catherine Staffeld-Coit; Paisit Paueksakon
Journal:  Ochsner J       Date:  2014

10.  Light chain deposition disease affecting the gastrointestinal tract in the setting of post-living donor kidney transplantation.

Authors:  Victor H Jimenez-Zepeda; Rajkumar Vajpeyi; Rohan John; Suzanne Trudel
Journal:  Int J Hematol       Date:  2012-05-10       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.